Artelo biosciences receives notice of allowance for method-of-use patent in the united states for art12.11, a proprietary cocrystal of cannabidiol

Solana beach, calif., march 02, 2022 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that the company received a notice of allowance from the u.s. patent and trademark office (uspto) for patent application 16/835,383 entitled “solid forms of cannabidiol and uses thereof” related to its art12.11 program, a cocrystal composition of cannabidiol (cbd). in addition, the company has pending foreign patent applications covering cocrystal composition-of-matter and method of use.
ARTL Ratings Summary
ARTL Quant Ranking